Vertex Pharmaceuticals Incorporated which can be found using ticker (VRTX) have now 25 confirmed analysts covering the stock with the consensus suggesting a rating of ‘buy’. The target price High/Low ranges between $456.00 and $325.00 calculating the mean target price we have $400.00. Given that the stocks previous close was at $354.78 this would indicate that there is a potential upside of 12.7%. It’s also worth noting that there is a 50 day moving average of $360.77 and the 200 day moving average is $338.63. The total market capitalization for the company now stands at 91.02B. The stock price for the company is currently $353.23 USD
The potential market cap would be $102,622,886,684 based on the market consensus.
The company is not paying dividends at this time.
Other points of data to note are a P/E ratio of 26.52, revenue per share of $37.49 and a 14.34% return on assets.
Vertex Pharmaceuticals Incorporated is a global biotechnology company. The Company is focused on developing medicines that treat the underlying cause of cystic fibrosis (CF). Its pipeline includes mid- and late-stage clinical programs in sickle cell disease, beta thalassemia, acute and neuropathic pain, APOL1-mediated kidney disease, type 1 diabetes, and alpha-1 antitrypsin deficiency, and earlier-stage programs in diseases such as muscular dystrophies. Its marketed medicines are TRIKAFTA/KAFTRIO (elexacaftor/tezacaftor/ivacaftor and ivacaftor), SYMDEKO/SYMKEVI (tezacaftor/ivacaftor and ivacaftor), ORKAMBI (lumacaftor/ivacaftor) and KALYDECO (ivacaftor). The Company has a pipeline of investigational small molecule, cell and genetic therapies in other serious diseases where it has deep insight into causal human biology, including sickle cell disease, beta thalassemia, APOL1-mediated kidney disease, pain, type 1 diabetes, alpha-1 antitrypsin deficiency and Duchenne muscular dystrophy.
